Duanrui Liu

Dr. Duanrui Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YLYunyun Liu
Yunyun Liu
BZBingkai Zhang
Bingkai Zhang
YZYimin Zhou
Yimin Zhou
YXYuanxin Xing
Yuanxin Xing
YWYunshan Wang
Yunshan Wang
DLDuanrui Liu
Duanrui Liu
The Hippo pathway plays an important role in cell proliferation, apoptosis, and differentiation; it is a crucial regulatory pathway in organ development and tumor growth. Infection with Helicobacter pylori (H. pylori) increases the risk of developing gastric cancer. In recent years, significant progress has been made in understanding the mechanisms by which H. pylori infection promotes the development and progression of gastric cancer via the Hippo pathway. Exploring the Hippo pathway molecules may yield new diagnostic and therapeutic targets for H. pylori-induced gastric cancer. The current article reviews the composition and regulatory mechanism of the Hippo pathway, as well as the research progress of the Hippo pathway in the occurrence and development of H. pylori-related gastric cancer, in order to provide a broader perspective for the study and prevention of gastric cancer.

5 June 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MYMingjie Yuan
Mingjie Yuan
XLXuekai Li
Xuekai Li
XSXuanli Song
Xuanli Song
XCXiaowei Chen
Xiaowei Chen
YWYunshan Wang
Yunshan Wang
DLDuanrui Liu
Duanrui Liu
Background Targeting lactate metabolism represents a promising therapeutic strategy to enhance anti-tumor immune responses. In this study, we developed a novel model based on lactate metabolism-related genes (LRGs) to predict survival, characterize the immune microenvironment, and assess immunotherapy response in gastric cancer (GC), with the potential to identify new biomarkers. Methods Data sets of GC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. LRGs were sourced from the MSigDB database. Five key prognostic LRGs (MMP11, MMP12, HBB, VSIG2, and SERPINE1) were identified using univariate COX regression and least absolute shrinkage and selection operator (LASSO) Cox regression analyses. Patients were classified into high-risk and low-risk groups based on a median risk score. We conducted prognostic analysis, gene set enrichment analysis (GSEA), immune microenvironment analysis, immunotherapy responsiveness evaluation, and drug screening in these groups. Results The high-risk group exhibited poorer prognosis compared to the low-risk group, as predicted by our nomogram for overall survival. Notably, the high-risk group, marked by higher stromal cell infiltration and RNA stemness scores (RNAss), showed increased susceptibility to immune evasion. In contrast, the low-risk group demonstrated better responses to immunotherapy and greater sensitivity to chemotherapy. Single-cell analysis revealed that SERPINE1 is predominantly positively correlated with immune checkpoint expression, while VSIG2 exhibits a negative correlation. Conclusions We have developed and validated a novel lactate metabolism-associated model, providing new insights into the prognosis and immunotherapy of GC patients. The five identified LRGs offer potential as prognostic biomarkers and therapeutic targets in GC.

4 March 2025 in JAMA
Verified
Journal Article
Closed access
DLDuanrui Liu
Duanrui Liu
AWAlice S. T. Wong
Alice S. T. Wong
YWYunshan Wang
Yunshan Wang